Not-so-sweet sixteen: The role of IL-16 in infectious and immune-mediated inflammatory diseases

Journal of Interferon and Cytokine Research

Volumn 26, Issue 8, 2006, Pages 511-520

  Glass, William G ^a   Sarisky, Robert T ^a   Del Vecchio, Alfred M ^a  

^a Immunobiology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CYTOKINE; INTERLEUKIN 16; INTERLEUKIN 2 RECEPTOR ALPHA;

ATOPIC DERMATITIS; CELL CYCLE G1 PHASE; CELL PROLIFERATION; DEGENERATIVE DISEASE; DISEASE EXACERBATION; HUMAN; IMMUNOPATHOLOGY; INFECTION; INFLAMMATION; IRRITABLE COLON; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; VIRUS INFECTION;

ANIMALS; AUTOIMMUNE DISEASES; DERMATITIS; HUMANS; INFECTION; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; INTERLEUKIN-16; MICE; MULTIPLE SCLEROSIS; RESPIRATION DISORDERS;

EID: 33747881230     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.2006.26.511     Document Type: Review

References (104)

1. Cruikshank W, Center DM. Modulation of lymphocyte migration by human lymphokines. II. Purification of a lymphotactic factor (LCF). J. Immunol. 1982;128:2569-2574.
2. Center DM, Cruikshank W. Modulation of lymphocyte migration by human lymphokines. I. Identification and characterization of chemoattractant activity for lymphocytes from mitogen-stimulated mononuclear cells. J. Immunol. 1982;128:2563-2568.
3. Bacon K, Baggiolini M, Broxmeyer H, Horuk R, Lindley I, Mantovani A, Maysushirna K, Murphy P, Nomiyama H, Oppenheim J, Rot A, Schall T, Tsang M, Thorpe R, Van Damme J, Wadhwa M, Yoshie O, Zlotnik A, Zoon K. Chemokine/chemokine receptor nomenclature. J. Interferon Cytokine Res. 2002;22:1067-1068.
4. Muhlhahn P, Zweckstetter M, Georgescu J, Ciosto C, Renner C, Lanzendorfer M, Lang K, Ambrosius D, Baier M, Kurth R, Holak TA. Structure of interleukin 16 resembles a PDZ domain with an occluded peptide binding site. Nat. Struct. Biol. 1998;5:682-686.
5. Baier M, Bannert N. Werner A, Lang K, Kurth R. Molecular cloning, sequence, expression, and processing of the interleukin 16 precursor. Proc. Natl. Acad. Sci. USA 1997;94:5273-5277.
6. + T cells in vitro. J. Immunol. 1996;156:310-315.
7. + T-cell infiltration with increased IL-16 gene expression in atopic dermatitis. J. Allergy Clin. Immunol. 1998;102:645-650.
8. Lim KG, Wan HC, Bozza PT, Resnick MB, Wong DT, Cruikshank WW, Kornfeld H, Center DM, Weller PF. Human eosinophils elaborate the lymphocyte chemoattractants. IL-16 (lymphocyte chemoattractant factor) and RANTES. J. Immunol. 1996;156:2566-2570.
9. + T lymphocyte chemoattractant factor, IL-16. J. Immunol. 1997;159:2904-2910.
10. + T cells is activation dependent. J. Immunol. 1999;162:1287-1293.
11. Bellini A, Yoshimura H, Vittori E, Marini M, Mattoli S. Bronchial epithelial cells of patients with asthma release chemoattractant factors for T lymphocytes. J. Allergy Clin. Immunol. 1993;92:412-424.
12. Center DM, Berman JS, Kornfeld H, Theodore AC, Cruikshank WW. The lymphocyte chemoattractant factor. J. Lab. Clin. Med. 1995;125:167-172.
13. Center DM, Kornfeld H, Cruikshank WW. Interleukin 16 and its function as a CD4 ligand. Immunol. Today 1996;17:476-481.
14. Theodore AC, Center DM, Nicoll J, Fine G, Kornfeld H, Cruikshank WW. CD4 ligand IL-16 inhibits the mixed lymphocyte reaction. J. Immunol. 1996;157:1958-1964.
15. (+) T cells with increases in viral loads in the chronic phase after vaccine-based partial control of primary simian immunodeficiency virus replication in macaques. J. Gen. Virol. 2004;85:1955-1963.
16. Mathy NL, Bannert N, Norley SG, Kurth R. Cutting edge: CD4 is not required for the functional activity of IL-16. J. Immunol. 2000;164:4429-4432.
17. Qi JC, Wang J, Mandadi S, Tanaka K, Roufogalis BD, Madigan MC, Lai K, Yan F, Chong BH, Stevens RL, Krilis SA. Human and mouse mast cells use the tetraspanin CD9 as an alternate interleukin-16 receptor. Blood 2006;107:135-142.
18. Center DM, Kornfeld H, Ryan TC, Cruikshank WW. Interleukin 16: implications for CD4 functions and HIV-1 progression. Immunol. Today 2000;21:273-280.
19. Alfano M, Poli G. Cytokine and chemokine based control of HIV infection and replication. Curr. Pharm. Des. 2001;7:993-1013.
20. Kornfeld H, Cruikshank WW. Prospects for IL-16 in the treatment of AIDS. Expert Opin. Biol. Ther. 2001;1:425-432.
21. Kedzierska K, Crowe SM, Turville S, Cunningham AL. The influence of cytokines, chemokines and their receptors on HIV-1 replication in monocytes and macrophages. Rev. Med. Virol. 2003;13:39-56.
22. Kedzierska K, Crowe SM. Cytokines and HIV-1: interactions and clinical implications. Antivir. Chem. Chemother. 2001;12:133-150.
23. Leung DY, Bhan AK, Schneeberger EE, Geha RS. Characterization of the mononuclear cell infiltrate in atopic dermatitis using monoclonal antibodies. J. Allergy Clin. Immunol. 1983;71:47-56.
24. Leung DY, Soter NA. Cellular and immunologic mechanisms in atopic dermatitis. J. Am. Acad. Dermatol. 2001;44:S1-S12.
25. Leung DY. Atopic dermatitis: new insights and opportunities for therapeutic intervention. J. Allergy Clin. Immunol. 2000;105:860-876.
26. Yawalkar N, Uguccioni M, Scharer J, Braunwalder J, Karlen S, Dewald B, Braathen LR, Baggiolini M. Enhanced expression of eotaxin and CCR3 in atopic dermatitis. J. Invest. Dermatol. 1999;113:43-48.
27. Taha RA, Minshall EM, Leung DY, Boguniewicz M, Luster A, Muro S, Toda M, Hamid QA. Evidence for increased expression of eotaxin and monocyte chemotactic protein-4 in atopic dermatitis. J. Allergy Clin. Immunol. 2000;105:1002-1007.
28. Kurita F. [Serum levels of NO products, IL-8, RANTES and eotaxin in infantile patients with atopic dermatitis]. Arerugi 2000;49:577-584.
29. Morita E, Kameyoshi Y, Hiragun T, Mihara S, Yamamoto S. The C-C chemokines, RANTES and eotaxin, in atopic dermatitis. Allergy 2001;56:194-195.
30. Kaburagi Y, Shimada Y, Nagaoka T, Hasegawa M, Takehara K, Sato S. Enhanced production of CC-chemokines (RANTES, MCP-1, MIP-1alpha, MIP-1beta, and eotaxin) in patients with atopic dermatitis. Arch. Dermatol. Res. 2001;293:350-355.
31. Hossny E, Aboul-Magd M, Bakr S. Increased plasma eotaxin in atopic dermatitis and acute urticaria in infants and children. Allergy 2001;56:996-1002.
32. Kagami S, Kakinuma T, Saeki H, Tsunemi Y, Fujita H, Nakamura K, Takekoshi T, Kishimoto M, Mitsui H, Torii H, Komine M, Asahina A, Tamaki K. Significant elevation of serum levels of eotaxin-3/CCL26, but not of eotaxin-2/CCL24, in patients with atopic dermatitis: serum eotaxin-3/CCL26 levels reflect the disease activity of atopic dermatitis. Clin. Exp. Immunol. 2003;134:309-313.
33. Shimada Y, Takehara K, Sato S. Both Th2 and Th1 chemokines (TARC/CCL17, MDC/CCL22, and Mig/CXCL9) are elevated in sera from patients with atopic dermatitis. J. Dermatol. Sci. 2004;34:201-208.
34. Masuda K, Katoh N, Okuda F, Kishimoto S. Increased levels of serum interleukin-16 in adult type atopic dermatitis. Acta Derm. Venereol. 2003;83:249-253.
35. Cheret A, Le Grand R, Caufour P, Neildez O, Matheux F, Theodore F, Boussin F, Vaslin B, Dormont D. Chemoattractant factors (IP-10, MIP-1alpha, IL-16) mRNA expression in mononuclear cells from different tissues during acute SIVmac251 infection of macaques. J. Med. Primatol. 1997;26:19-26.
36. + T lymphocytes in rheumatoid arthritis. Eur. J. Immunol. 1998;28:2661-2671.
37. Lorentz A, Schwengberg S, Sellge G, Manns MP, Bischoff SC. Human intestinal mast cells are capable of producing different cytokine profiles: role of IgE receptor cross-linking and IL-4. J. Immunol. 2000;164:43-48.
38. Mathy NL, Scheuer W, Lanzendorfer M, Honold K, Ambrosius D, Norley S, Kurth R. Interleukin-16 stimulates the expression and production of proinflammatory cytokines by human monocytes. Immunology 2000;100:63-69.
39. Vecchietti G, Kerl K, Hugli A, Samson J, Borradori L. Topical tacrolimus (FK506) for relapsing erosive stomatitis in paraneoplastic pemphigus. Br. J. Dermatol. 2003;148:833-834.
40. Reich K, Hugo S, Middel P, Blaschke V, Heine A, Gutgesell C, Williams R, Neumann C. Evidence for a role of Langerhans cell-derived IL-16 in atopic dermatitis. J. Allergy Clin. Immunol. 2002;109:681-687.
41. Reich K, Hugo S, Middel P, Blaschke V, Heine A, Neumann C. The maturation-dependent production of interleukin-16 is impaired in monocyte-derived dendritic cells from atopic dermatitis patients but is restored by inflammatory cytokines TNF-alpha and IL-1beta. Exp. Dermatol. 2004;13:740-747.
42. Yoshimoto T, Wang CR, Yoneto T, Matsuzawa A, Cruikshank WW, Nariuchi H. Role of IL-16 in ddayed-type hypersensitivity reaction. Blood 2000;95:2869-2874.
43. Masuda K, Katoh N, Soga F, Kishimoto S. The role of interleukin-16 in murine contact hypersensitivity. Clin. Exp. Immunol. 2005;140:213-219.
44. Frezzolini A, Paradisi M, Zaffiro A, Provini A, Cadoni S, Ruffelli M, De Pita O. Circulating interleukin 16 (IL-16) in children with atopic/eczema dermatitis syndrome (AEDS): a novel serological marker of disease activity. Allergy 2002;57:815-820.
45. Tanyasiri K, Hira K, Mitsuishi K, Ueki R, Sekigawa I, Ogawa H. Interleukin-16 in patients with alopecia areata. J. Dermatol. Sci. 2005;37:55-57.
46. + cytotoxic cells are present in increased numbers in the intestinal mucosa from patients with active inflammatory bowel disease. Am. J. Pathol. 1998;152:261-268.
47. James SP, Fiocchi C, Graeff AS, Strober W. Phenotypic analysis of lamina propria lymphocytes. Predominance of helper-inducer and cytolytic T-cell phenotypes and deficiency of suppressor-inducer phenotypes in Crohn's disease and control patients. Gastroenterology 1986;91:1483-1489.
48. Keates AC, Castagliuolo I, Cruiekshank WW, Qiu B, Arseneau KO, Brazer W, Kelly CP. Interleukin 16 is up-regulated in Crohn's disease and participates in TNBS colitis in mice. Gastroenterology 2000;119:972-982.
49. Seegert D, Rosenstiel P, Pfahler H, Pfefferkorn P, Nikolaus S, Schreiber S. Increased expression of IL-16 in inflammatory bowel disease. Gut 2001;48:326-332.
50. Schreiber S. Monocytes or T cells in Crohn's disease: does IL-16 allow both to play at that game? Gut 2001;49:747-748.
51. Glas J, Torok HP, Unterhuber H, Radlmayr M, Folwaczny C. The -295T-to-C promoter polymorphism of the IL-16 gene is associated with Crohn's disease. Clin. Immunol. 2003;106:197-200.
52. Lee S, Kaneko H, Sekigawa I, Tokano Y, Takasaki Y, Hashimoto H. Circulating interleukin-16 in systemic lupus erythematosus. Br. J. Rheumatol. 1998;37:1334-1337.
53. Lee S, Sekigawa I. [Possible pathogenic role of IL-16 on SLE: with reference to HIV-1 infection.] Ryumachi 1998;38:747-751.
54. Lard LR, Roep BO, Verburgh CA, Zwinderman AH, Huizinga TW. Elevated IL-16 levels in patients with systemic lupus erythematosus are associated with disease severity but not with genetic susceptibility to lupus. Lupus 2002;11:181-185.
55. Sekigawa I, Lee S, Kaneko H, Iida N, Hashimoto H, Hirose S, Kaneko Y. The possible role of interleukin-16 in the low incidence of HIV infection in patients with systemic lupus erythematosus. Lupus 2000;9:155-156.
56. Klimiuk PA, Goronzy JJ, Weyand CM. IL-16 as an anti-inflammatory cytokine in rheumatoid synovitis. J. Immunol. 1999;162:4293-4299.
57. Blaschke S, Schulz H, Schwarz G, Blaschke V, Muller GA, Reuss-Borst M. Interleukin 16 expression in relation to disease activity in rheumatoid arthritis. J. Rheumatol. 2001;28:12-21.
58. Kaufmann J, Franke S, Kientsch-Eugel R, Oelzner P, Hein G, Stein G. Correlation of circulating interleukin 16 with proinflammatory cytokines in patients with rheumatoid arthritis. Rheumatology (Oxford) 2001;40:474-475.
59. Kageyama Y, Ozeki T, Suzuki M, Ichikawa T, Miura T, Miyamoto S, Machida A, Nagano A. Interleukin-16 in synovial fluids from cases of various types of arthritis. Joint Bone Spine 2000;67:188-193.
60. Pritchard J, Horst N, Cruikshank W, Smith TJ. Igs from patients with Graves' disease induce the expression of T cell chemoattractants in their fibroblasts. J. Immunol. 2002;168:942-950.
61. Pritchard J, Tsui S, Horst N, Cruikshank WW, Smith TJ. Synovial fibroblasts from patients with rheumatoid arthritis, like fibroblasts from Graves disease, express high levels of IL-16 when treated with Igs against insulin-like growth factor-1 receptor. J. Immunol. 2004;173:3364-3569.
62. Mashikian MV, Ryan TC, Seman A, Brazer W, Center DM, Cruikshank WW. Reciprocal desensitization of CCR5 and CD4 is mediated by IL-15 and macrophage-inflammatory protein-1 beta, respectively. J. Immunol. 1999;163:3123-3130.
63. Lynch EA, Heijens CA, Horst NF, Center DM, Cruikshank WW. Cutting edge: IL-16/CD4 preferentially induces Th1 cell migration: requirement of OCRS. J. Immunol. 2003:171:4965-4968.
64. Bever CT Jr., Jacobson S, Mingioli ES, McFarland HF, McFarlin DE, Levy HB. Changes in leukocyte recirculation, NK cell activity, and HLA-DR expression in peripheral blood mononuclear cells of MS patients treated with poly ICLC. Int. J. Immunopharmacol. 1991;13:613-618.
65. Merelli E, Sola P, Faglioni P, Giordani S, Mussini D, Montagnani G. Natural killer cells and lymphocyte subsets in active MS and acute inflammation of the CNS. Acta Neurol. Scand. 1991;84:127-131.
66. Kondo T, Yamamura T, lnobe J, Ohashi T, Takahashi K, Tabira T. TCR repertoire to proteolipid protein (PLP) in multiple sclerosis (MS): homologies between PLP-specific T cells and MS-associated T cells in TCR junctional sequences. Int. Immunol. 1996;8:123-130.
67. Peters C, Lotzerich FL Raabe-Oekter A, Mucha C, Michna H. Functional activity of immune cells in female MS patients. Ann. Anat. 1998;180:321-325.
68. + T cells: potential roles in inflammation. J. Immunol. 1997;158:3046-3053.
69. + T-cell infiltration and improves paralysis and histopathology of relapsing EAE. J. Neurosci. Res. 2005;79:680-693.
70. Guo LH, Mittelbronn M, Brabeck C, Mueller CA, Schluesener HJ. Expression of interleukin-16 by microglial cells in inflammatory, autoimmune, and degenerative lesions of the rat brain. J. Neuroimmunol. 2004;146:39-45.
71. Suzuki T, Ishiguro A, Shimbo T. Transient elevation of interleukin-16 levels at the initial stage of meningitis in children. Clin. Exp. Immunol. 2003;131:484-489.
72. + T-lymphocytes and activated microglia/macrophages. J. Neuroimmunol. 2001;114:232-241.
73. Kurschner C, Yuzaki M. Neuronal interleukin-16 (NIL-16): a dual function PDZ domain protein. J. Neurosci. 1999;19:7770-7780.
74. Omri B, Crisanti P, Alliot F, Marty MC, Rutin J, Levallois C, Privat A, Pessac B. CD4 expression in neurons of the central nervous system. Int. Immunol. 1994;6:377-385.
75. Openshaw PJ. Immunity and immunopathology to respiratory syncytial virus. The mouse model. Am. J. Respir. Crit. Care Med. 1995;152:S59-62.
76. Kimpen JL, Garofalo R, Welliver RC, Fujihara K, Ogra PL. An ultrastructural study of the interaction of human eosinophils with respiratory syncytial virus. Pediatr. Allergy Immunol. 1996;7:48-53.
77. Stark JM, Godding V, Sedgwick JB, Busse WW. Respiratory syncytial virus infection enhances neutrophil and eosinophil adhesion to cultured respiratory epithelial cells. Roles of CD18 and intercellular adhesion molecule-1. J. Immunol. 1996;156:4774-4782.
78. Matthews SP, Tregoning JS, Coyle AJ, Hussell T, Openshaw PJ. Role of CCL11 in eosinophilic lung disease during respiratory syncytial virus infection. J. Virol. 2005;79:2050-2057.
79. Noah TL, Ivins SS, Murphy P, Kazachkova I, Moats-Staats B, Henderson FW. Chemokines and inflammation in the nasal passages of infants with respiratory syncytial virus bronchiolitis. Clin. Immunol. 2002;104:86-95.
80. Soukup JM, Becker S. Role of monocytes and eosinophils in human respiratory syncytial virus infection in vitro. Clin. Immunol. 2003;107:178-185.
81. Kotelkin A, Prikhod'ko EA, Cohen JI, Collins PL, Bukreyev A. Respiratory syncytial virus infection sensitizes cells to apoptosis mediated by tumor necrosis factor-related apoptosis-inducing ligand. J. Virol. 2003;77:9156-9172.
82. Qin XJ, Shi HZ, Huang ZX, Kang LF, Mo WN, Wu C. Interleukin-16 in tuberculous and malignant pleural effusions. Eur. Respir. J. 2005;25:605-611.
83. Wang C, Pang BS. Dynamic changes in blood cytokine levels as clinical indicators in severe acute respiratory syndrome. Chin. Med. J. (Engl.) 2003;116:1283-1287.
84. Robinson DS, Hamid Q, Ying S, Tsicopoulos A, Barkans J, Bentley AM, Corrigan C, Durham SR, Kay AB. Predominant Th2-like bronchoalveolar T-lymphocyte population in atopic asthma. N. Engl. J. Med. 1992;326:298-304.
85. Bradding P, Roberts JA, Britten KM, Montefort S, Djukanovic R, Mueller R, Heusser CH, Howarth PH, Holgate ST. Interleukin-4, -5, and -6 and tumor necrosis factor-alpha in normal and asthmatic airways: evidence for the human mast cell as a source of these cytokines. Am. J. Respir. Cell Mol. Biol. 1994;10:471-480.
86. Mashikian MV, Tarpy RE, Saukkonen JJ, Lim KG, Fine GD, Cruikshank WW, Center DM. Identification of IL-16 as the lymphocyte chemotactic activity in the bronchoalveolar lavage fluid of histamine-challenged asthmatic patients. J. Allergy Clin. Immunol. 1998;101:786-792.
87. Hessel EM, Cruikshank WW, Van Ark I, De Bie JJ, Van Esch B, Hofman G, Nijkamp FP, Center DM, Van Oosterhout AJ. Involvement of IL-16 in the induction of airway hyper-responsiveness and up-regulation of IgE in a murine model of allergic asthma. J. Immunol. 1998;160:2998-3005.
88. de Bie JJ, Henricks PA, Cruikshank WW, Hofman G, Nijkamp FP, van Oosterhout AJ. Effect of interleukin-16-blocking peptide on parameters of allergic asthma in a murine model. Eur. J. Pharmacol. 1999;383:189-196.
89. Krug N, Cruikshank WW, Tschernig T, Erpenbeck VJ, Balke K, Hohlfeld JM, Center DM, Fabel H. Interleukin 16 and T-cell chemoattractant activity in bronchoalveolar lavage 24 hours after allergen challenge in asthma. Am. J. Respir. Crit. Care Med. 2000;162:105-111.
90. Laberge S, Pinsonneault S, Varga EM, Till SJ, Noun-Aria K, Jacobson M, Cruikshank WW, Center DM, Hamid Q, Durham SR. Increased expression of IL-16 immunoreactivity in bronchial mucosa after segmental allergen challenge in patients with asthma. J. Allergy Clin. Immunol. 2000;106:293-301.
91. + cells in patients with allergic rhinitis. Allergy 2001;56:871-877.
92. El Bassam S, Pinsonneault S, Kornfeld H, Ren F, Menezes J, Laberge S. Interleukin-16 inhibits interleukin-13 production by allergen-stimulated blood mononuclear cells. Immunology 2006;117:89-96.
93. Pinsonneault S, El Bassam S, Mazer B, Cruikshank WW, Laberge S. IL-16 inhibits IL-5 production by antigen-stimulated T cells in atopic subjects. J. Allergy Clin. Immunol. 2001;107:477-482.
94. Spender LC, Cornish GH, Sullivan A, Farrell PJ. Expression of transcription factor AML-2 (RUNX3, CBF(alpha)-3) is induced by Epstein-Barr virus EBNA-2 and correlates with the B-cell activation phenotype. J. Virol. 2002;76:4919-4927.
95. Sauder C, Muller A, Cubitt B, Mayer J, Steinmetz J, Trabert W, Ziegler B, Wanke K, Mueller-Lantzsch N, de la Torre JC, Grasser FA. Detection of Borna disease virus (BDV) antibodies and BDV RNA in psychiatric patients: evidence for high sequence conservation of human blood-derived BDV RNA. J. Virol. 1996;70:7713-7724.
96. Sharmila C, Williams JW, Reddy PG. Effect of caprine arthritis- encephalitis virus infection on expression of interleukin-16 in goats. Am. J. Vet. Res. 2002;63:1418-1422.
97. + T cells mediate recovery and immunopathology in West Nile virus encephalitis. J. Virol. 2003;77:13323-13334.
98. Kelley TW, Prayson RA, Ruiz AI, Isada CM, Gordon SM. The neuropathology of West Nile virus meningoencephalitis. A report of two cases and review of the literature. Am. J. Clin. Pathol. 2003;119:749-753.
99. Glass WG, Subbarao K, Murphy B, Murphy PM. Mechanisms of host defense following severe acute respiratory syndrome-coronavirus (SARS-CoV) pulmonary infection of mice. J. Immunol. 2004;173:4030-4039.
100. Yu L, Wang Z, Jiang Y, Chang L, Kwang J. Characterization of newly emerging Newcastle disease virus isolates from the People's Republic of China and Taiwan. J. Clin. Microbiol. 2001;39:3512-3519.
101. Cotler SJ, Jensen DM. Treatment of hepatitis C virus and HIV co-infections. Clin. Liver Dis. 2001;5:1045-1061.
102. Ludwiczek O, Kaser A, Koch RO, Vogel W, Cruikshank WW, Tilg H. Activation of caspase-3 by interferon alpha causes interleukin-16 secretion but fails to modulate activation induced cell death. Eur. Cytokine Netw. 2001;12:478-486.
103. Cappelli G, Volpe P, Sanduzzi A, Sacchi A, Colizzi V, Mariani F. Human macrophage gamma interferon decreases gene expression but not replication of Mycobacterium tuberculosis: analysis of the host-pathogen reciprocal influence on transcription in a comparison of strains H37Rv and CMT97. Infect. Immun. 2001;69:7262-7270.
104. Coussens PM, Verman N, Coussens MA, Elftman MD, McNulty AM. Cytokine gene expression in peripheral blood mononuclear cells and tissues of cattle infected with Mycobacterium avium subsp. paratuberculosis: evidence for an inherent proinflammatory gene expression pattern. Infect. Immun. 2004;72:1409-1422.